New GLP-1 Addiction Treatment Platform Launches as Research on Cravings and SUD Continues

A Santa Fe, New Mexico-based startup called Quel Health launched this week what it describes as the first national telehealth company built specifically around prescribing GLP-1 medications for addiction — a move that puts a fast-growing category of consumer telehealth directly into a research area that is still, by the company's own account, investigational.

Quel Health's platform connects patients with affiliated providers through video evaluations, after which providers may prescribe GLP-1 medications off-label when they judge it clinically appropriate, alongside an individualized treatment plan and ongoing care support. The company says its providers have addiction expertise and that care includes medication management, health tracking, and messaging-based follow-up. Plans start at $149 a month after a free consultation, and the service is cash-pay only — it does not currently bill insurance. Quel says it's live in 41 states and Washington, D.C., with plans to reach all 50 states by the end of the year.

Caron Treatment Centers, one of the longer-running nonprofit addiction treatment providers in the country, is named as a founding strategic partner. In a statement, Caron's interim president and CEO described the relationship as a way to evaluate whether emerging approaches might responsibly expand access to care, while emphasizing that GLP-1 use for substance use disorders remains investigational and off-label — language that echoes the caution attached to this entire category of treatment so far.

01What GLP-1s Are Approved to Treat — and What They Aren't

GLP-1 receptor agonists — semaglutide and liraglutide are the two most studied in this context, sold under brand names including Ozempic, Wegovy, Victoza, and Saxenda — are FDA-approved for type 2 diabetes and, at certain doses, chronic weight management. They are not FDA-approved for any substance use disorder. Any prescription for that purpose, including through Quel Health's platform, is necessarily off-label, meaning a licensed prescriber is using clinical judgment to apply an approved drug to an unapproved indication rather than following an FDA-reviewed protocol specific to addiction. Quel Health's own materials acknowledge this directly, and it's a distinction worth keeping in view throughout the rest of this story: interest in GLP-1s for addiction is real and growing, but "investigated" is not the same as "approved," and "associated with" in a research study is not the same as "proven to treat."

02What the Research Actually Shows So Far

The evidence base behind this interest is genuinely active — more than 50 clinical trials examining GLP-1s for addiction are currently registered on ClinicalTrials.gov, according to Quel Health — but it's early, and it comes in two different forms that are worth distinguishing.

The larger, more frequently cited study is a Swedish national registry analysis published in JAMA Psychiatry in January 2025. Researchers followed patients with alcohol use disorder and coexisting obesity or type 2 diabetes over a median of more than eight years, comparing hospitalization risk during periods when patients were using a GLP-1 medication against periods when they weren't. Semaglutide use was associated with a substantially lower risk of AUD-related hospitalization (adjusted hazard ratio 0.64) and liraglutide with a somewhat smaller reduction (adjusted hazard ratio 0.72). That's a meaningful signal from a large, long-running dataset — but it's an observational study, not a randomized trial, which means it can show an association without being able to rule out that healthier or more treatment-engaged patients were simply more likely to be prescribed and to stay on a GLP-1 in the first place. The study's own authors describe the findings as reason for urgently needed clinical trials, not as confirmation.

A smaller but more direct piece of evidence comes from a randomized, placebo-controlled trial published in JAMA Psychiatry in February 2025, testing low-dose once-weekly semaglutide specifically in adults with alcohol use disorder. That trial reported reductions in craving and some drinking outcomes compared with placebo — a genuinely relevant kind of evidence, since randomization is what allows researchers to separate a drug's actual effect from the characteristics of who tends to get prescribed it. But the trial's own authors frame the results as justifying larger confirmatory trials rather than as an established finding, and it examined one medication, one dose, and one substance, over a limited window.

Other published and ongoing research has looked at GLP-1s in opioid use disorder, including among patients already on methadone, and at semaglutide for daily cigarette use, along with additional large real-world database analyses linking GLP-1 prescriptions to lower rates of alcohol and cannabis use disorder recurrence. None of this amounts to an established, guideline-recommended treatment protocol for any substance use disorder at this point — it amounts to a genuinely active and reasonably promising research direction that has not yet cleared the bar of controlled evidence needed for FDA review or inclusion in standard clinical treatment guidelines.

03Where This Leaves the Category

Quel Health is not alone in exploring the intersection of GLP-1 medications and addiction treatment, and the underlying scientific question — whether drugs that alter appetite and reward-related brain signaling might also blunt cravings for alcohol, nicotine, or other substances — is one a substantial and growing body of researchers is actively working on. What launched this week is a distribution model: a telehealth platform structured to get patients in front of prescribers willing to use these drugs off-label, backed by a partnership with an established treatment provider and explicit acknowledgment, from both the company and its partner, that this remains investigational.

That framing matters for how the news should be read. A telehealth company launching around an emerging treatment approach is a business and access story as much as a clinical one — it says something about investor and provider interest in this research direction, and about how quickly consumer telehealth is willing to move into off-label prescribing for behavioral health conditions. It does not, on its own, change what the underlying evidence supports. As of this launch, GLP-1 medications remain an active, unapproved, off-label area of addiction research — one with real signal in early studies, and one still waiting on the larger, randomized trials that its own researchers say are needed before anyone can call the question settled.